Jennifer Woyach, MD, Reflects on the Liso-Cel Approval for CLL

(4:25)

ASH Impact Series: Jennifer Woyach, MD – The Latest CLL Research in Relation to New Drug Therapies

(5:20)

Why Jennifer Woyach, MD, Chose to Work at the OSUCCC – James

(28)

Dr. Woyach on the Role of Acalabrutinib in CLL

(1:39)

Dr. Woyach on the Role of Small Molecule Inhibitors in CLL

(1:8)

Dr. Woyach on Ibrutinib Resistance in CLL

(1:47)

Dr. Woyach on the Role of Chemoimmunotherapy in CLL

(1:25)

BTKi Resistance Mutations in Chronic Lymphocytic Leukemia (CLL)

(30:28)

Impact of Ibrutinib Treatment on T-Cell Exhaustion in CLL - ASH 2023 Dr. Jennifer Woyach

(5:55)

Evolution of BTK Inhibitors in CLL

(5:6)

The Haslam 3 Foundation Donates $2 Million to Pelotonia

(3:23)

LP-168: a novel next-generation BTK inhibitor with dual activity in CLL

(2:57)

2021 Pelotonia-Funded Researcher of the Year Award, awarded to Jennifer Woyach, MD

(2:20)

An Overview of a Study Combining MOR208 With Lenalidomide in CLL

(1:2)

Ibrutinibe - ASH 2018 - Jennifer Woyach

(2:59)

Novel Therapies for CLL

(8:56)

Dr. Woyach Discusses Peripheral Lymphocytosis in Patients with CLL Taking Ibrutinib

(1:26)

Dr. Woyach on Ibrutinib and Peripheral Lymphocytosis in Patients with Chronic Lymphocytic Leukemia

(1:16)

Jennifer Woyach, MD, Discusses BRUIN CLL-322 Design, Enrollment Process

(2:12)

Dr. Woyach on the Safety of Acalabrutinib Versus Ibrutinib in CLL

(1:3)

Dr. Woyach Discusses Progression on Ibrutinib With the Acquisition of Resistance Mutations

(1:17)

Dr. Woyach on Clinical Trials Examining Novel Triplets in CLL

(1:21)

Dr. Woyach Discusses the Efficacy Findings from the RESONATE Trial

(28)

Dr. Woyach Discusses Efficacy Findings from the RESONATE Trial

(40)

Jennifer Woyach, MD, Highlights Novel CLL Therapies Presented at ASH 2023

(9:47)

The future of CLL treatment: more selective and reversible BTK inhibitors

(2:59)

Dr. Woyach Discusses Progression on Ibrutinib With the Acquisition of Resistance Mutations

(1:31)

Dr. Woyach on Using Ibrutinib in Combination Therapies

(1:53)

Woyach on the Safety Profiles of BTK Inhibitors in CLL

(1:37)